ADVERTISEMENT

Gymnastics lands grad transfer from Michigan

Landing folks from the transfer portal is all the rage, with Jordyn Wieber taking a page out of the Eric Musselman playbook now...

Here's the UA press release:

FAYETTEVILLE – Head gymnastics coach Jordyn Wieber has announced that Maggie O’Hara, a University of Michigan graduate, will be joining the Arkansas Gymbacks for the 2020-2021 season.

“We are thrilled to welcome Maggie to the Arkansas Gymnastics family,” said Wieber. “I am looking forward to seeing her contributions to our team this upcoming season on bars and beam. She has a wealth of experience in NCAA gymnastics already and is ready to be a leader, both in the gym and in the classroom.”

O’Hara’s wealth of experience comes in the form of four decorated years for Michigan gym. She finished her career for the Wolverines with 9.875s as career highs on both the uneven bars and balance beam, both achieved during the 2020 campaign. O’Hara competed in eights meets in 2020, making four appearances on the bars and seven appearances on the beam.

In 2019, O’Hara suffered a season-ending injury, but not before making her uneven bars debut at the Cancun Classic and scoring a 9.825 at the meet.

Since O’Hara arrived in Ann Arbor, Michigan has earned three consecutive Big Ten Championship titles in 2017-2019 and a regular-season conference title in 2020 before the season was canceled due to COVID-19. The Wolverines finished the season ranked No. 5 in the nation by Road to Nationals.

O’Hara graduated from Michigan in the spring of 2020 with a degree in movement science and will pursue her master’s degree in kinesiology at Arkansas. Born in Lexington, South Carolina, Maggie is the daughter of Matthew and Michele O’Hara and has three siblings, Sean, Daniel and Gracie.

SEC Returning Offensive Production(The Athletic)

Pass Yards
1. Tennessee (100%)
1. Texas A&M (100%)
3. Auburn (97%)
4. South Carolina (95%)
5. Florida (92%)
6. Kentucky (72%)
7. Alabama (34%)
8. Arkansas (18%)
9. Missouri (17%)
10. Georgia (8%)
11. LSU (6%)
12. Vanderbilt (0%)

Rush Yards
1. Tennessee (97%)
2. Alabama (94%)
3. Missouri (85%)
4. Arkansas (83%)
5. Texas A&M (75%)
6. Kentucky (59%)
7. Auburn (52%)
8. Florida (48%)
9. Georgia (33%)
10. LSU (29%)
11. Vanderbilt (24%)
12. South Carolina (23%)

Receiving Yards
1. Auburn (74%)
2. Arkansas (73%)
3. Texas A&M (67%)
4. Kentucky (59%)
5. Alabama (57%)
5. Georgia (57%)
7. LSU (51%)
8. Missouri (48%)
9. Florida (45%)
10. South Carolina (43%)
11. Vanderbilt (40%)
12. Tennessee (31%)

OL Starts
1. Tennessee (91%)
2. Kentucky (80%)
2. South Carolina (80%)
2. Texas A&M (80%)
5. Arkansas (77%)
6. Alabama (74%)
7. Florida (68%)
8. Vanderbilt (57%)
9. Georgia (42%)
9. Missouri (42%)
11. LSU (21%)
12. Auburn (8%)

Pass Game Returning Production (50% Pass Yd, 30% Rec Yd, 20% OL Start)
1. Texas A&M (86.1%)
2. Tennessee (77.5%)
3. South Carolina (76.4%)
4. Florida (73.1%)
5. Auburn (72.3%)
6. Kentucky (69.4%)
7. Alabama (48.9%)
8. Arkansas (46.3%)
9. Missouri (31.3%)
10. Georgia (29.6%)
11. Vanderbilt (23.4%)
12. LSU (22.5%)


Run Game Returning Production (60% Rush Yd, 40% OL Starts)
1. Tennessee (94.6%)
2. Alabama (86.0%)
3. Arkansas (80.6%)
4. Texas A&M (77.0%)
5. Missouri (67.8%)
6. Kentucky (67.3%)
7. Florida (56.0%)
8. South Carolina (45.8%)
9. Vanderbilt (37.2%)
10. Georgia (36.7%)
11. Auburn (34.4%)
12. LSU (25.8%)


Total Offense (each 4 areas make up 25% each of total)
1. Texas A&M (80.5%)
2. Tennessee (79.8%)
3. Kentucky (67.3%)
4. Alabama (64.8%)
5. Florida (63.3%)
6. Arkansas (62.8%)
7. South Carolina (60.3%)
8. Auburn (57.8%)
9. Missouri (48.0%)
10. Georgia (35.1%)
11. Vanderbilt (30.3%)
12. LSU (26.8%)
  • Like
Reactions: DaltonG and Mass31

Promising vaccine news

Login to view embedded media 1,700 person study, 90% of people created antibodies after one dose, the others did after two doses.

They still don't know how long the antibodies will last or just how protective it may be. Side effects so far have been fever and headache.

"The trial has also been expanded to other countries because levels of coronavirus are low in the UK, making it hard to know if the vaccine is effective.

There will be a large trial involving 30,000 people in the US as well 2,000 in South Africa and 5,000 in Brazil.

There are also calls to perform "challenge trials" in which vaccinated people are deliberately infected with coronavirus. However, there are ethical concerns due to a lack of treatments."
ADVERTISEMENT

Filter

ADVERTISEMENT